S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
LON:GSK

GSK (GSK) Share Price, News & Analysis

GBX 1,708.60
+3.40 (+0.20%)
(As of 03/28/2024 05:14 PM ET)
Today's Range
1,699.21
1,713
50-Day Range
1,521.20
1,711.20
52-Week Range
1,302.60
1,719.80
Volume
8.50 million shs
Average Volume
7.41 million shs
Market Capitalization
£69.37 billion
P/E Ratio
1,423.83
Dividend Yield
3.75%
Price Target
GBX 1,658.75

GSK MarketRank™ Stock Analysis

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
2.9% Downside
GBX 1,658.75 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.56
Upright™ Environmental Score
News Sentiment
0.75mentions of GSK in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
£231.78 M Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.04 out of 5 stars

GSK stock logo

About GSK Stock (LON:GSK)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

GSK Stock Price History

GSK Stock News Headlines

A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
GSK plc (LON:GSK) Insider Urs Rohner Buys 434 Shares of Stock
GSK to cap out-of-pocket inhaler costs in US
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
GSK Mar 2024 41.000 call
GSK Mar 2024 34.000 put
How DEI is helping GSK get ahead of disease
GSK drug meets goal in late-stage gonorrhea study
See More Headlines
Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/29/2020
Ex-Dividend for 1/11 Dividend
11/16/2023
Dividend Payable
1/11/2024
Ex-Dividend for 4/11 Dividend
2/22/2024
Today
3/29/2024
Dividend Payable
4/11/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
70,212
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 1,658.75
High Stock Price Target
GBX 1,950
Low Stock Price Target
GBX 1,300
Potential Upside/Downside
-2.9%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
£4.93 billion
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£30.33 billion
Cash Flow
GBX 209.76 per share
Book Value
GBX 329 per share

Miscellaneous

Outstanding Shares
4,060,000,000
Free Float
N/A
Market Cap
£69.37 billion
Optionable
Not Optionable
Beta
0.26
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Ms. Emma Natasha Walmsley (Age 55)
    CEO & Director
    Comp: $5.39M
  • Ms. Julie Belita Brown (Age 62)
    CFO & Executive Director
    Comp: $5.14M
  • Ms. Shobie Ramakrishnan (Age 53)
    Chief Digital & Technology Officer
  • Mr. Tony Wood
    Chief Scientific Officer and Head of R&D
  • Ms. Sarah Elton-Farr
    Head of Investor Relations
  • Mr. James Ford
    Senior VP & Group General Counsel of Legal & Compliance
  • Ms. Sally Jackson
    Senior Vice President of Global Communications & CEO Office
  • Mr. David Simon Redfern BSc (Hons) (Age 58)
    CA, President of Corporate Development
  • Ms. Diana Conrad
    Chief People Officer
  • Mr. Philip C. Thomson
    President of Global Affairs

Should I Buy GSK Stock? GSK Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in GSK plc:

  • GSK plc has shown consistent growth in revenue and earnings, indicating financial stability and potential for returns.
  • Recent analyst ratings and target prices suggest a positive outlook for the stock, with potential upside for investors.
  • The company's stock price has been performing well, showing resilience and potential for capital appreciation.
  • GSK plc has a diverse portfolio of pharmaceutical products, reducing risk associated with dependency on a single product.
  • Strong institutional investor interest in GSK plc indicates confidence in the company's future performance.

Cons

Investors should be bearish about investing in GSK plc for these reasons:

  • GSK plc's debt-to-equity ratio is relatively high, which may pose risks in terms of financial leverage and interest payments.
  • The company's P/E ratio is high, suggesting the stock may be overvalued compared to its earnings potential.
  • GSK plc's beta indicates lower volatility compared to the market, potentially limiting short-term trading opportunities for investors.
  • The current ratio of GSK plc is below 1, indicating potential liquidity challenges in meeting short-term obligations.
  • Market competition and regulatory challenges in the pharmaceutical industry could impact GSK plc's growth prospects and market share.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, March 25, 2024. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com.

GSK Stock Analysis - Frequently Asked Questions

Should I buy or sell GSK stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings
or view top-rated stocks.

What is GSK's stock price target for 2024?

7 brokers have issued 12-month price objectives for GSK's shares. Their GSK share price targets range from GBX 1,300 to GBX 1,950. On average, they anticipate the company's share price to reach GBX 1,658.75 in the next year. This suggests that the stock has a possible downside of 2.9%.
View analysts price targets for GSK
or view top-rated stocks among Wall Street analysts.

How have GSK shares performed in 2024?

GSK's stock was trading at GBX 1,450.20 at the beginning of the year. Since then, GSK shares have increased by 17.8% and is now trading at GBX 1,708.60.
View the best growth stocks for 2024 here
.

How were GSK's earnings last quarter?

GSK plc (LON:GSK) issued its quarterly earnings results on Wednesday, July, 29th. The company reported $56.90 EPS for the quarter. GSK had a net margin of 16.25% and a trailing twelve-month return on equity of 46.38%.

How often does GSK pay dividends? What is the dividend yield for GSK?

GSK announced a dividend on Wednesday, January 31st. Shareholders of record on Thursday, February 22nd will be given a dividend of GBX 16 per share on Thursday, April 11th. This represents a dividend yield of 1.04%. The ex-dividend date of this dividend is Thursday, February 22nd. This is an increase from the stock's previous dividend of GBX 14. The official announcement can be accessed at this link.
Read our dividend analysis for GSK
.

Is GSK a good dividend stock?

GSK (LON:GSK) pays an annual dividend of GBX 64 per share and currently has a dividend yield of 3.89%. The dividend payout ratio is 5,333.33%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for GSK.

What other stocks do shareholders of GSK own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AstraZeneca (AZN), General Electric (GE), Royal Dutch Shell (RDSB), Vodafone Group Public (VOD), Intel (INTC), NVIDIA (NVDA), Johnson & Johnson (JNJ), AT&T (T), Barclays (BARC) and Gilead Sciences (GILD).

How do I buy shares of GSK?

Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:GSK) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners